* Revenue rises 45 percent
* Expects Canadian decision on antidepressant drug
TORONTO, Nov 11 (Reuters) - Canada’s Labopharm Inc DDS.TO, which specializes in controlled-release drugs, posted on Thursday a wider net loss as higher sales and marketing expenses offset improved revenue.
For the third quarter, Labopharm posted a net loss of C$7.2 million, or 10 Canadian cents a share. This compared with a net loss of C$6.9 million, or 12 Canadian cents a share, for the same quarter a year earlier.
Revenue was up 45 percent, at C$9.6 million, bolstered by C$3.7 million in licensing-related payments and deferred revenue.
The company also said it is anticipating a Canadian decision by the end of the year on its drug submission for once-daily antidepressant drug, trazodone. ($1=$1 Canadian) (Reporting by Solarina Ho, editing by Gerald E. McCormick)